Truist Financial Increases Quest Diagnostics (NYSE:DGX) Price Target to $150.00

Quest Diagnostics (NYSE:DGX) had its price target increased by Truist Financial from $145.00 to $150.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “hold” rating on the medical research company’s stock. Truist Financial’s target price indicates a potential upside of 9.99% from the company’s current price.

A number of other research firms have also weighed in on DGX. SVB Leerink assumed coverage on shares of Quest Diagnostics in a research note on Monday, February 26th. They set a “market perform” rating and a $135.00 target price on the stock. Barclays began coverage on shares of Quest Diagnostics in a research note on Wednesday, January 3rd. They issued an “equal weight” rating and a $145.00 price target on the stock. Leerink Partnrs reiterated a “market perform” rating on shares of Quest Diagnostics in a research note on Monday, February 26th. Jefferies Financial Group upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and increased their price target for the company from $140.00 to $155.00 in a research note on Wednesday, February 7th. Finally, TheStreet lowered shares of Quest Diagnostics from a “b-” rating to a “c” rating in a research note on Monday, February 5th. Ten analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $145.50.

Quest Diagnostics Stock Down 0.2 %

Shares of NYSE:DGX opened at $136.38 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.31 and a quick ratio of 1.20. The firm has a market capitalization of $15.15 billion, a PE ratio of 18.21, a price-to-earnings-growth ratio of 2.81 and a beta of 0.91. The firm’s 50-day moving average is $128.50 and its two-hundred day moving average is $131.03. Quest Diagnostics has a 1 year low of $119.59 and a 1 year high of $148.62.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.18. The company had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.29 billion. Quest Diagnostics had a net margin of 9.23% and a return on equity of 15.79%. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.04 earnings per share. Analysts predict that Quest Diagnostics will post 8.75 EPS for the current year.

Insider Activity

In other news, SVP Michael E. Prevoznik sold 661 shares of Quest Diagnostics stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total value of $83,378.54. Following the sale, the senior vice president now owns 40,206 shares of the company’s stock, valued at $5,071,584.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, SVP Michael E. Prevoznik sold 661 shares of Quest Diagnostics stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total value of $83,378.54. Following the sale, the senior vice president now owns 40,206 shares of the company’s stock, valued at $5,071,584.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Catherine T. Doherty sold 821 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $126.14, for a total transaction of $103,560.94. Following the sale, the executive vice president now directly owns 70,800 shares in the company, valued at approximately $8,930,712. The disclosure for this sale can be found here. Insiders have sold a total of 15,150 shares of company stock valued at $1,913,202 over the last quarter. Corporate insiders own 0.79% of the company’s stock.

Institutional Trading of Quest Diagnostics

A number of institutional investors have recently added to or reduced their stakes in DGX. Altshuler Shaham Ltd acquired a new position in Quest Diagnostics during the fourth quarter worth about $26,000. NBC Securities Inc. acquired a new position in Quest Diagnostics during the third quarter worth about $25,000. BKM Wealth Management LLC acquired a new position in Quest Diagnostics during the fourth quarter worth about $29,000. VisionPoint Advisory Group LLC raised its position in Quest Diagnostics by 100.0% during the third quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after acquiring an additional 109 shares during the last quarter. Finally, Spartan Planning & Wealth Management acquired a new position in Quest Diagnostics during the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.